[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[$regns](/topic/$regns)

### Top Social Posts

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"@cremieuxrecueil From $REGNs acquisition of $DBTX decibel therapeutics Reminded me to check the terms of the CVRs of the shares I used to own"  
[X Link](https://x.com/ThinkPatient/status/1979288194484178965) [@ThinkPatient](/creator/x/ThinkPatient) 2025-10-17T20:47Z XXX followers, XX engagements


"$CLPT fanatics have been screaming about this for years now. The lowest risk gene cell therapy programs you can make are for the CNS"  
[X Link](https://x.com/AB1001_disciple/status/1977777641811014077) [@AB1001_disciple](/creator/x/AB1001_disciple) 2025-10-13T16:45Z XXX followers, 3559 engagements


"It looks like AAV gene therapy is finding its niche: local delivery of relatively low doses (E10-E12 total vg) in tissues as contained as possible. Recent clinical wins by $QURE's AMT-130 (intra-parenchymal Huntington's) and $REGN's DB-OTO (intracochlear inherited deafness) support this trend. These follow prior approved drugs like $RHHBY's Luxturna (subretinal LCA2) and $PTCT's Upstaza (intra-parenchymal AADC deficiency) also delivered locally. $NVS' Zolgensma is a special case -- although delivered systemically at relatively high doses the infant BBB remains permissive allowing efficient"  
[X Link](https://x.com/GerardCaelles/status/1977771288660791721) [@GerardCaelles](/creator/x/GerardCaelles) 2025-10-13T16:19Z 1099 followers, 13.8K engagements